| Formulary Chapter 5: Infections - Full Chapter
|
|
| Details... |
| 05.03.01 |
HIV infection |
|
|
|
|
| 05.03.01 |
Nucleoside reverse transcriptase inhibitors |
|
|
Abacavir (Ziagen®)
|
Formulary
|
|
|
|
Emtricitabine (Emtriva®)
|
Formulary
|
|
|
|
Lamivudine
|
Formulary
|
Tablets
Oral Solution
|
|
|
Tenofovir Disproxil (Viread®)
|
Formulary
|
|
 NICE CG165: Hepatitis B (chronic) - incorporates TA173
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
|
Zidovudine (Retrovir®)
|
Formulary
|
Capsules
Oral Solution
Injection
|
PAHT: HIV in Pregnancy
|
Abacavir and Lamivudine (Kivexa®)
|
Formulary
|
Tablets
|
|
|
Abacavir and Lamivudine and Zidovudine (Trizivir®)
|
Formulary
|
|
|
|
Emtricitabine 200mg, Rilpivirine 25mg and Tenofovir 245mg (Eviplera®)
|
Formulary
|
|
|
|
Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg (Atripla®)
|
Formulary
|
|
|
|
Tenofovir alafenamide and Emtricitabine (Descovy®)
|
Formulary
|
 Requires MDT discussion with ID team
|
|
|
Tenofovir alafenamide, Emtricitabine and Rilpivirine (Odefsey®)
|
Formulary
|
Tablet
Requires MDT discussion with ID team
|
|
|
Tenofovir alafenamide, Emtricitabine, Elvitegravir and Cobicistat (Genvoya®)
|
Formulary
|
Tablet
Requires MDT discussion with ID team
|
MHRA Safety Alert: Cobicistat coadministration with a corticosteroid
|
Tenofovir and Emtricitabine (Truvada®)
|
Formulary
|
|
NICE Evidence Summary: Pre-exposure prophylaxis of HIV in adults at high risk: Truvada
|
Tenofovir, cobicistat, elvitegravir & emtricitabine (Stribild®)
|
Formulary
|
Tablets
Requires MDT discussion with ID team
|
MHRA Safety Alert: Cobicistat coadministration with a corticosteroid
 NHS England Commissioning Policy
|
Zidovudine and Lamivudine (Combivir®)
|
Formulary
|
|
|
|
Didanosine (Videx®)
|
Formulary
|
Tablets
Capsules
Only for patients already established on this treatment.
|
|
|
Stavudine (Zerit®)
|
Formulary
|
Capsules
Oral Solution
Only for patients already established on this treatment
|
|
|
| 05.03.01 |
Protease inhibitors |
|
|
| 05.03.01 |
Non-nucleoside reverse transcriptase inhibitors |
|
|
| 05.03.01 |
Other antiretrovirals |
|
|
| 05.03.01 |
Pharmacokinetic enhancers of antiretrovirals |
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Drugs designated amber are suitable for shared care arrangements under a shared care protocol.
Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.
|
|
These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products. |
|
Not used
|
|
Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care. |
|
Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required. |
|
Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required. |
|
Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient. |
|
Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.
|
|
|
|
